Home > Journals > Minerva Ginecologica > Past Issues > Minerva Ginecologica 2014 February;66(1) > Minerva Ginecologica 2014 February;66(1):85-9





A Journal on Obstetrics and Gynecology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index




Minerva Ginecologica 2014 February;66(1):85-9

language: English

Effect of metformin on the level of anti-Mullerian hormone in therapy of polycystic ovary syndrome in obese women

Grigoryan O., Absatarova J., Andreeva E., Melnichenko G., Dedov I.

Endocrinology Research Centre, Moscow, Russia


Aim: Anti-Mullerian hormone (AMG) reduction in women with hyperinsulinemia in therapy with metformin suggests that metformin affects the level of AMH and ovulatory dysfunction through insulin-mediated mechanisms. Aim of the study was to assess the effects of metformin hydrochloride (Siofor) on the level of AMH in women with polycystic ovary syndrome and obesity.
Methods: The study involved 40 women with PCOS, aged 22 to 35 years (mean age 28.7±5.2 years) with body mass index (BMI) 32.5±4.3 kg/m2. All patients received metformin hydrochloride (Siofor) orally, 1 tablet (850 mg) two times a day for six months. After three and six months of therapy anthropometric characteristics, concentration of hormones in the blood serum were assessed.
Results: In patients receiving Siofor a decrease of BMI, waist-hip ratio (P<0.05), concentration of T, as well as free androgen index (FAI) (P<0.01) was shown. Furthermore, there was a decrease in ovarian volume by 12%. AMH concentration during therapy did not changed significantly.
Conclusion: The hypothesis that a decline in AMG level is a consequence of the reduced BMI, which was significant in the group of women with hyperinsulinemia, does not seem convincing in view of the fact that patients with a normal insulin level also showed a trend to lower BMI, which, however, was not accompanied by a decrease in its concentration.

top of page

Publication History

Cite this article as

Corresponding author e-mail